Fundraising Fox
bioline
NASDAQ: BLRXModi'In · Israel corporation · 1 known investors
Find your way into bioline
Sign up to see every warm intro you have to bioline
- Paths you didn't know you had: your email and LinkedIn already hold routes to the bioline team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Bioline Rx develops therapies for patients with cancer and rare diseases, leveraging a team with expertise spanning drug development from chemistry through clinical trials to commercialization.
Founders & leadership
PA
Philip A. SerlinExecutive
AV
Board
AM
Avraham MolchoBoard director
MJ
Michael J. AnghelBoard director
SP
Sandra PanemBoard director
SY
Shaoyu YanBoard director
BJ
Barbara Jean BormannBoard director
RH
Raphael HofsteinBoard director
AS
Aharon SchwartzBoard director
NB
Nurit BenjaminiBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$17.1M disclosed across 3 rounds · 2020–2026
▶$3.8MraisedSep 2026 · 1 investors · BiotechnologyRule 506(b)
▶$3.8MraisedSep 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Philip A. SerlinExecutive Officer
- Mali ZeeviExecutive Officer
- Ella SoraniExecutive Officer
- Aharon SchwartzDirector
- Rami DarDirector
- BJ BormannDirector
- Raphael HofsteinDirector
- Avraham MolchoDirector
- Sandra PanemDirector
- Shaoyu YanDirector
- Gal CohenDirector
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- Sales commissions
- $262.5K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Aug 2026
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$9MraisedJun 2020 · 6 investors · PharmaceuticalsRule 506(b)
▶$9MraisedJun 2020 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Barbara Jean BormannDirector
- Mali ZeeviExecutive Officer
- Raphael HofsteinDirector
- Avraham MolchoDirector
- Philip A. SerlinExecutive Officer
- Aharon SchwartzDirector
- Nurit BenjaminiDirector
- Abi Vainstein-HarasExecutive Officer
- Michael J. AnghelDirector
- Sandra PanemDirector
- Ella SoraniExecutive Officer
- Offering amount
- $9M
- Amount sold
- $9M
- Sales commissions
- $630K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- May 2020
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$4.4MraisedJun 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$4.4MraisedJun 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Abi Vainstein-HarasExecutive Officer
- Avraham MolchoDirector
- Philip A. SerlinExecutive Officer
- Nurit BenjaminiDirector
- Michael J. AnghelDirector
- Mali ZeeviExecutive Officer
- Ella SoraniExecutive Officer
- Sandra PanemDirector
- Raphael HofsteinDirector
- Barbara Jean BormannDirector
- Aharon SchwartzDirector
- Offering amount
- $4.4M
- Amount sold
- $4.4M
- Sales commissions
- $307.5K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- May 2020
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does bioline do?
- Bioline Rx develops therapies for patients with cancer and rare diseases, leveraging a team with expertise spanning drug development from chemistry through clinical trials to commercialization.
- Who are bioline's investors?
- bioline's investors include Kreos Capital.
- How much funding has bioline raised?
- bioline has disclosed $17.1M raised across 3 rounds.
- Where is bioline headquartered?
- bioline is headquartered in Modi'In.